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EVALUATING THE QUALITY OF ONLINE HEALTH INFORMATION ABOUT 
PROSTATE CANCER TREATMENT 
JASON GARWING LEE 
ABSTRACT 
Background 
Prostate cancer is one of the most common cancers amongst men, yet it is a surprisingly 
complex disease.  There are currently multiple options for treatment, depending on the 
stage of the cancer, with new methods currently under investigation.  Patients can easily 
get confused about these treatments including the risks/benefits of each, even after 
consulting a urologist.  Consequently, patients have been increasingly using the internet 
to learn about various diseases, including prostate cancer.  However, because online 
health information is largely unregulated in the United States, it can be difficult for 
patients to accurately determine the quality of a website. 
Objective 
The purpose of this study is to evaluate the readability and quality of websites describing 
prostate cancer treatments.  This study hypothesizes that in general, most websites will be 
both too difficult to read for an average patient, and of an inferior quality. 
Methods 
This study is a review of websites that could potentially be found by a patient just 
diagnosed with prostate cancer.  Two search engines, Google and Bing, were used with 
the search terms “prostate cancer” and “prostate cancer treatments”.  To evaluate each 
website’s readability, three readability formulas were used (Flesch-Kincaid Grade Level, 
 
 vi
Flesch-Kincaid Reading Ease, and SMOG), while the DISCERN tool was used to 
evaluate each website’s quality.  These scores will be analyzed using a two-tailed, one 
sample t-test to evaluate whether the readability of prostate cancer treatment websites is 
more difficult than the AMA/NIH recommended 7th grade level as well as if there is a 
difference in quality between advertisement and non-advertisement sponsored websites. 
Results 
40 unique websites were found and 26 of them were analyzed for this study. 7 of these 
websites were marked as advertisements.  The average readability of prostate cancer 
treatment websites was around an 11th grade reading level, which was significantly higher 
than the AMA/NIH recommended 7th grade level.  Based on DISCERN, there was a 
significant difference in quality between the advertisement and non-advertisement 
websites with the average quality of non-advertisement websites being rated as “Good”, 
while advertisement websites were rated as “Poor”. 
Conclusion 
We found that the internet can provide high quality prostate cancer information for 
patients.  However, many of these websites require a high school education to properly 
interpret.  Overall, the internet can act as a useful and informative supplement to a 
patient’s healthcare.   However, given the variable quality of websites, it is important for 
medical professionals to take an active role in how their patient’s obtain medical 
information. Medical professionals need to ensure that their own websites are updated 
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Prostate cancer is one of the most common cancers in the world.  Approximately 
one of seven men will be diagnosed with prostate cancer within his lifetime, and virtually 
all adult men will be undergo some type of prostate screening.1  This screening typically 
consists of a digital rectal exam, a blood test called PSA, and/or imaging.  Although 
prostate cancer is typically symptomless, the disease course can range from being 
indolent for years to being very aggressive and possibly fatal.  Depending on the stage of 
cancer, treatment options for prostate cancer range from active surveillance, surgery, and 
radiation for localized prostate cancer versus hormonal therapy and/or chemotherapy for 
advanced prostate cancer.  Other newer treatment methods include immunotherapy, 
cryotherapy, and high-intensity focused ultrasound.   
Consequently, prostate cancer has been a large focus of urological research, 
ranging from what are appropriate screening practices, discovering new genetic 
biomarkers, to developing new treatment modalities.  While this research has provided 
prostate cancer patients with an abundance of options to meet their treatment goals, it can 
also cause a lot of confusion for patients.  In order to fully understand all of their options, 
many patients will do research outside of their urologist’s office. 
Statement of the Problem 
The internet has become an increasingly popular medical resource for patients 
with a study in 2011 finding that 80% of internet users searched for some type of health 
information online.2  Patients are now able to access a seemingly infinite amount of 
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information from the convenience and privacy of their own homes, and become more 
active competent agents in their own healthcare.  However, it is difficult to regulate 
online health information due to freedom of speech, so legal interventions are reserved 
for information that is deemed obviously dangerous to the public.3  As a result, biased 
and even false information can be published by anyone, leaving patients responsible for 
determining the reliability of a website.  Additionally, the readability of a website can be 
problematic; many patients may not have enough health literacy to properly understand 
and interpret the medical jargon required to accurately and thoroughly describe cancer 
treatments.  If patients trust online resources of a poor quality or those that they do not 
truly understand, they can end up making important medical decisions that are 
misinformed.  Poor healthcare could result in the wrong treatment being performed, 
delayed treatment with possible progression of disease, or overtreatment with detrimental 
side effects.   
Hypothesis 
Online health information on prostate cancer treatments, as a whole, is inadequate 
in both the quality/accuracy and readability of information. 
Objectives and specific aims 
It is the purpose of this thesis to review current prostate cancer treatments, discuss 
the various reasons why patients utilize the internet for healthcare purposes, and to 
perform a study evaluating the current state of online health information on prostate 
cancer treatments.  While most of the literature on prostate cancer focuses on novel 
screening/treatment techniques, it is still profoundly important that patients understand 
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the benefits and risks of these treatments.  It is the hope that this thesis will illuminate the 
importance of evaluating online health information for all diseases. 
 
The specific aims of the project include: 
• Review how current prostate cancer patients utilize the internet to complement 
their healthcare. 
• Evaluate websites about prostate cancer treatments based on two factors -- how 
readable the text is for the average American patients and the quality of the 




REVIEW OF THE LITERATURE 
Epidemiology of prostate cancer 
Prostate cancer is the most common cancer diagnosed and the second most 
common cause of cancer death in American men. In 2019, there were an estimated 
174,650 new cases of prostate cancer and 31,620 deaths.4  There is approximately a one 
in seven risk of a man developing prostate cancer within his lifetime.1  
There are many unmodifiable risk factors that have been associated with the 
development of prostate cancer, including age, family history, and ethnicity.  Age is a 
strongly related risk factor for prostate cancer with the average age of diagnosis being 66 
years of age.  Diagnosis is rare before the age of 40 and risk increases almost 17-fold 
after age 55.1,5 Family history is another strongly associated risk factor.  Men with a 
father or brother with prostate cancer are 2-3 times more likely to develop prostate cancer 
than men with a negative family history; this risk increases with an increased number of 
diagnosed first-degree relatives.  There is also an increased risk of death from prostate 
cancer if a family member has also died from prostate cancer.5 There are significant 
differences in prostate cancer incidence across racial groups (Figure 1), with African 
Americans having the highest incidence and mortality and Asian Americans, Hispanics, 
and American Indians having a lower incidence than Caucasians.5  The reasons for these 
disparities are most likely multifactorial with diet, medical history, and socioeconomic 
factors such as access to healthcare playing a role.  Additionally, after controlling for 
these factors, African Americans were still almost two times more likely to be diagnosed 
with prostate cancer, suggesting a possible genetic component.6  There are also many 
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modifiable risk factors connected to prostate cancer that have been identified including: a 
diet high in saturated fat, red meat, and dairy, obesity, and occupations with pesticides.  







Figure 1: Prostate cancer incident and mortality rates (age-adjusted per 100,000) by race/ethnicity in the United 
States, 2010-2014. (Figure based on SEER Registry Data)5 
 
Pathophysiology 
The prostate is a gland of the male reproductive system located inferior to the 
bladder and anterior to the rectum, with the urethra running through the center.  Its main 
function is to produce a fluid added to seminal fluid to help nourish and protect sperm.  
The development and function of the prostate is highly dependent on androgens, 
particularly testosterone and dihydrotestosterone, with previous studies showing prostate 
shrinkage in the setting of androgen deprivation.7  Anatomically, the prostate is split into 
several different zones; the peripheral zone, transition zone, central zone, and anterior 
fibromuscular stroma.8  The peripheral zone consists of around 70% of the prostate and is 
the most common area for prostate cancer growth.  The transitional zone, which 




the prostate that grows in patients with benign prostatic hyperplasia, a common disease of 
prostate enlargement.  The central zone consists of 25% of prostate tissue and surrounds 
the ejaculatory ducts, with the seminal vesicles located superior.8 The anterior 
fibromuscular stroma is made of striated and smooth muscles, and assists with both 
voluntary and involuntary sphincter functions.9  This extends into a fibromuscular band 
that covers the majority of the prostate, which, while referred to as the prostate capsule, is 
not considered a true capsule.10  The prostate is highly innervated by both the 
parasympathetic and sympathetic divisions that help regulate prostate growth and 
maturation.  There are also neurovascular bundles on the posterolateral aspects of the 
prostate that are crucial for erectile function.8  Histologically, the glandular portion of the 
prostate is composed of ducts and acini made from secretory epithelial cells, basal cells, 
and endocrine-paracrine cells.  In patients with prostate cancer, the acinar cells become 
abnormal and poorly differentiated and there should be no basal cells.10   
The exact cause of prostate cancer is unknown but, in general prostate cancer is 
caused by mutations, either inherited or acquired, in a cell’s DNA that causes 
uncontrolled cell growth, impaired DNA repair and/or impaired cell death.  The vast 
majority of prostate cancers (95%) are classified as acinar adenocarcinoma, while the 
more rare types include urothelial, small cell, squamous, and basal cell carcinoma.10  
Prostate cancer is a relatively slow-growing disease but progresses similarly to other solid 
tumors, and can grow through the capsule, known as extraprostatic extension (EPE), and 
into surrounding structures such as the seminal vesicles.  If untreated, prostate cancer can 
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metastasize to any other part of the body, most commonly to bone followed by lymph 
nodes, liver, and thorax.11 
Screening 
There are many screening modalities for prostate cancer, each of varying 
helpfulness.  One of the oldest is the digital rectal exam (DRE), during which the 
physician inserts a finger into the rectum to palpate the prostate for any nodules or 
unusual textures.  However, the usefulness of this exam has been called into question due 
to its low sensitivity (.51) and specificity (.59)12, inconsistent interpretations13, and the 
inability to palpate the entire prostate, as the DRE cannot examine the anterior and 
midline aspects of the prostate.14  While some recommend that DRE not be performed, 
especially due to its intrusive and anxiety-causing nature, it is still commonly performed 
as an adjunct screening method by urologists. 
The most common and one of the most controversial methods of screening is the 
PSA test.  PSA is an enzyme produced and secreted by the epithelial cells of the prostate 
that digests gel-forming proteins to help liberate sperm.15  The majority of PSA is 
secreted into the seminal fluid but minor amounts can be detected in blood serum in due 
to backflow into the extracellular fluid.  In patients with prostate cancer, the architecture 
of the prostatic ducts is disrupted causing increased levels of PSA in the serum.  
Traditionally, a PSA level of above 4μg/L indicates a possible need for biopsy.15 While 
prostate cancer diagnosis has increased in incidence since the widespread use of PSA 
testing in the late 1980s and early 1990s (Figure 2), some question its benefits.16  Since 
prostate cancer is slow-growing, many of these patients’ prostate cancer diagnoses may 
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have never become clinically significant/symptomatic throughout their lifetime. 
Overdiagnosis of prostate cancer can lead to psychological distress and overtreatment, 
which is accompanied by excess medical costs and side effects that can be debilitating to 
daily life.14  Additionally, a PSA level cutoff of 4μg/L was only found to have a specificity 
of .60, due to many non-malignant etiologies causing an elevated PSA level, such as BPH, 
prostatitis, urinary retention, and any type of instrumentation of the prostate such as a 
biopsy.14  This can result in multiple unnecessary biopsies, which can be traumatic and have 
their own potentially severe side effects.  On the other hand, PSA testing is easy to obtain, 
inexpensive, and there has been a decrease in mortality and increase in 5-year-survival rates 
(68% in the 1970s to 100% in the 200s) since the popularization of PSA testing (Figure 2).17 
While this is thought to be due to multiple factors, such as more aggressive treatment, studies 
have estimated that 45-70% of these changes can be attributed to changes in screening.18   
   
Figure 2: Age-adjusted prostate cancer incidence rates (Left) and prostate mortality rates (Right) for all ages 
and rates from 1975-2011 (From National Cancer Institute, 2015.)17 
Two large-scale studies have been performed in order to further elucidate this relationship, 
the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial and the European 
Randomized Study of Screening for Prostate Cancer (ERSPC).  The results, however, were 
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contradictory as PLCO showed no significant difference in mortality between a treatment 
group offered yearly screening and a control group, while ERSPC showed a significant 
decrease in mortality in the group with PSA screening compared to the control group.19,20  
Consequently, the professional guidelines for prostate cancer screening significantly differ.  
While all agree that screening should be a shared-decision process between patient and 
physician, the US Preventative Task Force (UPSTF) does not recommend routine screening 
for prostate cancer.  This includes African American men and those with a family history of 
prostate cancer as UPSTF believes that there is not enough evidence to suggest that screening 
confers a significant benefit to patients, even those with risk factors.  On the other hand, the 
American Urological Association (AUA) recommends discussions about screening should 
begin by age 55, and the ACS recommends even earlier if the patient has significant risk 
factors, as discussed earlier.21–23  
If clinically suggested (Positive DRE/High PSA Level) and with patient consent, a 
biopsy of the prostate can be obtained.  Currently, the AUA recommends that urologists 
perform a transrectal ultrasound guided (TRUS) 12-core biopsy, using a template distribution 
sampling each section of the prostate including the lateral and apical regions (Figure 3).24  
Taking additional cores has not been shown to significantly increase the rate of detecting 
clinically significant cancer, but did increase the rate of detecting insignificant prostate 
cancer.25  If the initial biopsy is negative and prostate cancer is still suspected, additional 
cores, such as with a saturation biopsy, can be collected especially in under-sampled 
regions.25  Prostate biopsies are accompanied by side effects, most commonly hematuria, 
rectal bleeding, and hematospermia but these are typically mild and resolve on their own. 
Urinary tract infections (UTI), acute urinary retention, and erectile dysfunction (ED) can also 
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occur, but are rarer.25  The most concerning side effects are sepsis and bacteremia, a 4% rise 
in 30-day admission rates following a TRUS biopsy, most likely due to antibiotic 
resistance.26  Infection prophylaxis should be given to all patients receiving a biopsy with 
special attention given to patients with a high risk of infection. 
 
Figure 3: Template for TRUS 12-core biopsy (LBL: Left Base Lateral, LBM: Left Base Medial, RBM: Right 
Base Medial, RBL: Right Base Lateral, LML: Left Mid Lateral, LMM: Left Mid Medial, RMM: Right Mid 
Medial, RML: Right Mid Lateral, LAL: Left Apical Lateral, LAM: Left Apical Medial, RAM: Right Apical 
Medial, RAL: Right Apical Lateral)24 
The use of magnetic resonance imaging (MRI) for prostate cancer care is not 
novel, as it is commonly used in the pretreatment setting to determine whether EPE, 
neurovascular bundle invasion, or seminal vesicle invasion is present.27  While not 
currently recommended as a mainstream screening modality, some studies have found 
MRI to have aa sensitivity of .89 and specificity of .73 for prostate cancer detection.28  
MRI can also be used to guide targeted biopsies instead of ultrasound.  While there has 
been no significant difference found in how often prostate cancer is detected between 
TRUS and MRI guided biopsies, there is evidence that MRI guided biopsies detect 
clinically significant cancer more often and insignificant cancer less often than TRUS 
biopsies.29,30  However, there is still a lack of consensus on the role of MRI, who should 
be getting screening MRIs, and whether MRI-guided biopsies can replace TRUS-guided 
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biopsies, so both procedures are often done together.  Additionally, MRIs are much 
costlier than ultrasounds so the decision to obtain an MRI should be shared.    
Lastly, research on new screening techniques, such as novel urine/blood biomarkers 
(PCA3) or risk models (4KSCORE), is underway to help men elucidate their prostate 
cancer risk and need for screening.  However, these are not currently standard of care and 
are of secondary use when more information is desired.14 
Treatment 
The standard treatments for clinically localized prostate cancer include 
surgery/radical prostatectomy, radiation therapy, and active surveillance.  The staging of 
the cancer helps guide what treatment is recommended for a patient.  The AJCC 
(American Joint Committee on Cancer) TMN system is widely used to stage prostate 
cancer and incorporates Gleason score, PSA level, the extent of the tumor (T), lymph 
node involvement (N), and metastasis (M).31  The Gleason grading system was created 
from a study performed in 1960s.32  A Gleason score is assigned to both prostate biopsy 
and prostatectomy samples based on how histologically similar a malignant prostate cell 
is to a normal one based on architectural features; scores range from 1, meaning well 
differentiated cells, to 5, meaning poorly differentiated cells.  Because prostate cancer 
can be heterogenous with two or more grades of cancer present, the Gleason score is 
represented as a mathematical equation (Example: Gleason Score 3+4=7) with the first 
number representing the most prevalent grade and the second representing the second 
most prevalent grade.9  Historically, Gleason scores could range from 2 (1+1) to 10 
(5+5), but in 2014 several changes were made to the grading system.  One major change 
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is that Gleason grades of 1 and 2 are no longer assigned for prostate biopsies due to poor 
reproducibility and evidence showing that Gleason 1+1=2 cancer was often adenosis 
instead of malignancy.32  Gleason scoring for prostate biopsies were also changed; the 
first number still represents the most prevalent histological pattern but now the second 
number represents the highest non-dominant histological pattern, as the randomized 
nature of biopsies makes it impossible to know how much high-grade prostate cancer is 
actually present.  For prostatectomy samples, the Gleason score still consists of the two 
most prevalent grades but a tertiary grade can be assigned if a low volume higher grade 
adenocarcinoma exists.10,32  In order simplify the grading system for patients and help 
guide treatment, the International Society of Urological Pathology (ISUP) proposed a 
grade grouping schema that more accurately reflects the natural biology and prognosis of 
prostate cancer (Table 1).  Of note is the separation of Gleason 3+4=7 and Gleason 
4+3=7, as Gleason 4+3=7 cancer has been noted to have a worse prognosis.32   
Table 1. Grade Group schema proposed by ISUP 
Grade Group Gleason Score Gleason Pattern Risk Group 
1 ≤ 6 ≤ 3+3 Low 
2 7 3+4 Intermediate Favorable 
3 7 4+3 Intermediate Unfavorable 
4 8 4+4, 3+5, 5+3 High 
5 9 or 10 4+5, 5+4, 5+5 High 
 
Radical prostatectomy i.e. removal of the prostate is a common treatment for 
patients with localized prostate cancer, although it is not the recommended treatment for 
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patients with very low-to-low risk prostate cancer or metastatic cancer.33 A prostatectomy 
can be done with an open approach, but minimally invasive techniques, such as 
laparoscopic prostatectomy (LP) and particularly robotic assisted radical prostatectomy 
(RARP), are much more common now.  Open prostatectomy and minimally invasive 
techniques are thought to have similar outcomes in cancer control, complication rate, and 
urinary and sexual function recovery, but LP/RARP are associated with less blood loss 
and shorter hospital stay.34  Minimally invasive techniques have also been found to 
produce positive surgical margins less often, but the surgeon’s prior surgery 
volume/experience, regardless of technique, has also been shown to be a significant 
contributing factor.35,36  Prostatectomy is often accompanied by a pelvic 
lymphadenectomy especially in patients with high risk prostate cancer.   
Due to the close proximity of the neurovascular bundles and the bladder to the prostate, 
impotence and urinary incontinence, especially immediately after surgery, are common 
side effects of a prostatectomy.33  Urologists will attempt to preserve the neurovascular 
bundles during surgery, but sometimes this is not feasible if the tumor has spread 
extensively.27  Recovery of sexual function occurs with or without medical intervention 
over time and is more likely in patients whose nerves were spared and in younger 
patients.37  Patients will typically develop stress incontinence, or loss of bladder control 
with movement or increased pressure on the bladder, but most do not report significant 
life interference and regain normal function over time, particularly in younger patients.38 
Radiation therapy (RT) for prostate cancer uses high doses of radiation in the 
form of x-rays or protons to damage the DNA of malignant cells, killing the tumor while 
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preserving normal structures.39 There are two main groups of radiation, external beam 
radiation therapy (EBRT) and brachytherapy.  Brachytherapy is when a radioactive 
source is temporarily or permanently directly inserted into the prostate.39  It can be used 
as a monotherapy treatment for low-risk cancer, but studies have also shown that 
combination therapy of brachytherapy and EBRT reduces recurrence for high-risk 
prostate cancer.40  For EBRT, radiation delivered from an external source, it is now 
standard to use dose-escalated and intensity-modulated RT with image guidance in order 
to kill malignant cells with reduced radiation toxicity to nearby organs. Stereotactic and 
hypofractionation RT approaches, where a higher radiation dose is delivered in fewer 
treatments, can also be used for lower risk disease as it has been shown to have a similar 
treatment efficacy but is more convenient for patients.39  EBRT is recommended for 
patients with localized prostate cancer, but can also be used as symptomatic treatment for 
advanced disease and recurrent disease post-surgery.33  Radiation using protons instead of 
x-rays can also be used for prostate cancer, but it is not commonly performed in the US. 
Side effects of RT are largely due to irradiation of nearby healthy tissue, particularly the 
rectum and bladder, causing radiation proctitis and cystitis respectively.41  Increased 
doses of radiation, which improves the chance of curative treatment, increases these side 
effects, but technological developments have reduced their incidence.42  Gastrointestinal 
symptoms, such as diarrhea and rectal bleeding, are still the most common side effects 
within the first two years of treatment but they abate in most patients over time.  Urinary 
symptoms, such as hematuria and frequency, can occur following treatment, but long-
term side effects like urinary incontinence are much rarer with RT than surgery.  
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However, obstructive urinary symptoms including retention can be common with 
brachytherapy so it is usually discouraged in patients with previous symptoms or those 
who have undergone a transurethral resection of the prostate.42  ED can also occur with 
RT but it is typically not acute, as with surgery, but develops over time. 
Because prostate growth is dependent on androgen hormones such as testosterone, 
androgen deprivation therapy (ADT) can be used as an adjunct treatment to RT for 
intermediate and high-risk prostate cancer or as the primary treatment for metastatic 
cancer.  ADT can be performed either by orchiectomy, surgical removal of the testicles, 
or much more commonly medically, with gonadotrophin-releasing-hormone agonists.33  
The side effects of ADT, including hot flashes, gynecomastia, decrease in libido, ED, and 
fatigue, are mostly due to low testosterone.  Lowered bone mineral density and anemia 
are also common but often asymptomatic.  ADT has also been found to exacerbate 
metabolic syndrome, particularly hyperlipidemia and insulin resistance, and while there is 
thought to be an association with cardiac death and cognitive impairment, there is little 
evidence to support this.43 
Because prostate cancer often grows slowly and can remain indolent throughout 
one’s lifetime, patients can postpone treatment indefinitely or until the disease becomes 
clinically significantly, known as active surveillance.  This approach is the recommended 
treatment for patients with localized very low to low risk prostate cancer (Grade Group 1 
with a low PSA).  Active surveillance is also an option for patients with intermediate-
favorable cancer (Grade Group 2 with low cancer and Gleason 4 volume) but there is a 
higher chance of metastases compared to treatment.33  Patients undergoing active 
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surveillance need to be monitored for clinical progression with screening modalities such 
as PSA tests, DRE, and prostate biopsies/MRI.  The primary benefit of active 
surveillance is the avoidance of detrimental side effects and high medical costs associated 
with treatment, especially if the cancer would not have caused clinical harm.  The risk of 
pursuing active surveillance is possibly not detecting and finding high-risk prostate 
cancer.  While one trial found that patients on active surveillance had a significantly 
higher chance of developing metastases than treatment groups, there was no difference in 
prostate cancer related mortality.44  Additionally, another trial found less than a 1% 
chance of metastases in active surveillance patients at 10 and 15 years.45 
 
Existing research 
While prostate cancer is a relatively common diagnosis, it is still a complex 
disease given all of the risk factors, screening modalities, varied treatments, and the 
abundance of research and clinical trials being performed.  Consequently, there is an 
overwhelming amount of information available. One study, performed by Leonard et al. 
in 2016, aimed to describe how aware the general population was of prostate cancer, 
particularly screening techniques and risk factors.46  Adult men (N=470), who presented 
to the Stony Brook University Emergency Department in Long Island, NY were studied 
as this population was thought to be comparable in racial demographics and education 
levels to the US population, per the US census.  Patients who had an altered mental 
status, were in critical care, or did not speak English were excluded from the study.  Data 
was collected via oral surveys and analyzed via chi-square tests for categorical variables 
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and t-tests for continuous variables.  The majority of patients had heard of prostate cancer 
(96%) and DRE/prostate exam (89%), and about half had heard of PSA tests (47%), but 
there were significant disparities amongst many demographic groups (p<.001).  In 
particular, Hispanic and African American men were significantly less aware of various 
screening modalities.46  The study also found that only 13% of African American men 
knew that they were at a higher risk of developing prostate cancer and less than half of 
men with a first-degree relative with prostate cancer were aware they were high risk for 
their lifetime.  However, a table with this data was not included in the paper which is one 
limitation of this study.  Other limitations include a possible selection bias since the study 
was performed in one location, as well as a potential for recall bias since all the surveys 
were done orally in a potentially high-stress environment.  Additionally, the study 
population ideally could have attempted to include more African American men given 
their increased risk for prostate cancer, and non-English speakers since this population is 
vulnerable to being misinformed about medicine.  What this study demonstrates is that 
while many men are aware of prostate cancer, there is a large number of men, particularly 
minorities, who are unaware of the screening methods and risk factors for prostate 
cancer.  This could potentially delay diagnosis, leading to more severe disease and 
invasive treatment.  Overall, there is clearly room for more education regarding prostate 
cancer.  
Where patients receive medical information has changed as technology develops 
with resources such as the internet becoming more popular.  One study, performed in 
2018 in Canada by Stewart et al., aimed to describe how patients obtain information 
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about prostate cancer once diagnosed and the barriers to do so.47  Men who were 
diagnosed with prostate cancer in the last half of 2012, and therefore two years after 
diagnosis, were eligible for the study.  Surveys were mailed to participants and were 
focused on information needs/decision-making immediately after diagnosis, current 
needs, internet use, and demographic information.  In total, 1366 patients were included 
in the study. Chi square testing was utilized, but most data was reported in percentages.  
The results demonstrated that patients get prostate cancer information from a variety of 
resources.  Unsurprisingly, patients most often obtained information from their urologist 
(86%), with 65% consulting the internet, and 81% using printed media.  The survey also 
asked about which treatments each participant was informed about; the majority of 
participants were informed about prostatectomy (75%) and radiation therapy (65%), 
while only 36% of participants were told about active surveillance.  While offered 
treatments are dependent on staging, it is still surprising that less than half of patients 
knew about active surveillance.  Additionally, 36% of patients who had surgery did not 
receive information about radiation therapy, even though both are used for the same stage 
of cancer, showing a disparity in offered treatments.  Despite the amount of available 
resources, 19% of participants still felt somewhat or poorly informed about prostate 
cancer/treatments, which could be explained by the barriers to obtaining information 
from these resources.  Many participants felt that their consultations with their urologists 
were limited by not having enough time and being worried about asking too many 
questions.  Additionally, many patients receive information from their urologist 
immediately after diagnosis, the anxiety from which can hinder a person’s ability to 
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process information and ask important questions.48  While some participants were unsure 
of how to determine the quality of the information, the internet is a relatively widely used 
resource that can help fill these gaps in prostate cancer knowledge.  One limitation of this 
study was that the surveys were administered two years after a patient’s diagnosis.  Since 
the data focused on patients’ experiences immediately after diagnosis, there is the 
potential for recall bias.  Racial demographics were also not collected which limits the 
generalizability of the study, as there are discrepancies in medical knowledge and internet 
usage between different populations. 
In order to further elaborate on the advantages and disadvantages of using the 
internet for obtaining medical knowledge, a qualitative study was performed in 2004 by 
Ziebland et al to gain a better understanding of why men and women with cancer use the 
internet.49  Ziebland used interviews collected by DIPEx International, a research 
association that collects health narratives for a variety of diseases, with 175 interviews 
from men and women with prostate (49), testicular (37), breast (37), cervical (21), and 
bowel cancer (31) included in the study.50  In these interviews, internet usage was 
mentioned throughout all stages of cancer diagnosis/treatment. Two of the major benefits 
that attracted patients to the internet were convenience, as patients found that many of 
their questions arose outside of their consultations, and privacy.  Patients found they were 
able to reaffirm their doctor’s advice covertly, either giving them reassurance and 
improving future consultations or redirecting their care to avenues more suited to their 
lifestyle goals without endangering the doctor-patient relationship.  Obtaining a greater 
understanding of their disease, granted patients the ability to display competence, which 
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has been shown to empower patients causing them to become more engaged and willing 
to make positive differences in their life.51  Aside from gaining knowledge, the internet 
also improved mental health by reducing isolation via online support groups and 
narratives of other’s experiences.  Participants also had negative commentary about their 
experiences with the internet with some finding the vast amount of information 
overwhelming and unwanted, such as survival rates.  There were also concerns about the 
accuracy of the information as the regulation of online health advice is difficult given US 
free speech laws with intervention primarily reserved for websites that display dangerous 
information.3  Limitations of the study include the fact that it was performed 15 years 
ago, when the landscape of the internet was different, and that no statistical analysis 
could be done.  This is largely due to the fact that the interviews used were meant to 
represent a diverse group of patients, not the population as a whole numerically.  
However, this study still gives reliable accounts of various ways cancer patients use the 
internet to their benefit, and how it can change how patients approach their own 
healthcare. 
Because African American men are at a higher risk for prostate cancer and are 
historically underrepresented in clinical trials, it is important understand how this specific 
population obtains medical information.  In 2014, Song et al. aimed to learn more about 
how low-income primarily African American men sourced information about general 
health and prostate cancer and how this affected their prostate screening awareness and 
screening behaviors.52  Men in Milwaukee, MN were recruited from a senior center 
prostate-screening event, an employment services meeting at a local church, and a 
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waiting area at a Milwaukee Health Department clinic via posters and flyers.  Eligibility 
requirements include being older than 40, owning a cell phone, and having previous 
prostate cancer screening.  Data was collected via surveys inquiring about preferred 
medium for health information and prostate cancer awareness, based on a five-point 
scale, with an incentive of $20 once completed.  Prostate cancer screening history was 
determined with yes/no questions.  Of those that completed the survey (N=90), 91% were 
African American, 77% had an annual household income of $0 to $25,000, and 60% did 
not have health insurance.  Many did not have reliable access to the internet with 59% not 
having access at home and 44% stating that they never used the internet.  Overall, 
participants primarily sought out personal interactions for health information such as 
health professionals (M = 3.93, SD = 1.87) and family and friends (M = 3.58, SD = 2.12) 
over the internet (M = 2.65, SD = 1.84), which can partially be explained by the large 
percentage of the participants who did not regularly use or understand the internet.  
However, regression analysis found that there were benefits for those that used the 
internet as the use of internet resources (eB = 1.65, p < .05) and health professionals (eB = 
.48, p < .001) significantly predicted increased prostate cancer screening, while personal 
resources (eB = 1.13, p=.61) did not.  This makes sense as while family members and 
friends may be more trusted and easier to access, they may have limited knowledge about 
prostate cancer screening.  Additionally, paired t-tests showed that participants sought out 
information about general health significantly more than prostate cancer for all resources.  
Previous studies have shown that this disparity could be due to embarrassment of a 
prostate cancer diagnosis due to its association with sexual dysfunction, in which case, 
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the internet would be an excellent resource to utilize and maintain privacy.53  While there 
are barriers to accessing the internet for low income and/or minority populations, this 
study shows that using the internet can still be a valuable and beneficial resource for 
prostate cancer information.  One limitation of this study is the eligibility requirement to 
own a cell phone.  Considering that technology use was a focus of the study, this could 
introduce selection bias by excluding those who may not have the technological expertise 
to use a cell phone.  Additionally, while factors such as income level and recruitment site 
were controlled for, education was not which similarly could have an effect on how adept 
one is at using technology and how likely one is to know about/receive prostate cancer 
screening. 
Age is another important risk factor for prostate cancer, and previous studies have 
shown that there are disparities in the use of internet for health information when 
differentiated by age.54  Rising et al. conducted a study in 2015 to discover how men of 
different ages diagnosed with prostate cancer view and use eHealth.55  289 men were 
recuited from online prostate cancer social networks and the Inova Health System.  
Surveys were used to collect data on demographics, prostate cancer history, and one’s 
internet behavior/reasons for using prostate cancer eHealth resources.  Because of the 
source of recruitment, most of the participants were educated beyond a high school level 
and white (95.8%), which is a limitation on this study’s generalizability.  The data was 
separated into cohorts of men older and younger than 65, and analyzed with chi-square, 
ANOVA, and Kendall’s tau-b correlation coefficient testing.  The study found that men 
in the younger cohort used the internet more frequently (F = 3.80, P = .05) and were more 
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comfortable using the internet (F = 6.31, P = .01).  Furthermore, those who understood 
how to use the internet (tau-b =.16, P =.004) and apply it to their own situation (tau-b 
=.15, P =.004) were associated with positive psychosocial indicators, such as confidence 
and feeling in control, while those who had difficulty in internet use (tau-b = -.11, P = 
.04) were negatively associated with those indicators.  The study explains these findings 
through a mediation model (Figure 4) which showed an indirect negative effect of age on 
positive psychosocial indicators when mediated by internet use (b = .0.10, 95% CI -0.28 
to 0).  This suggests that while the internet can have a positive effect on psychological 
factors, the older cohort did not have enough knowledge of the internet resulting in 
negative psychosocial experiences.   
            
Figure 4: Mediation model: The effect of age on positive psychosocial indicators through Internet use.55 
 
While both cohorts used the internet to search for medical information, the 
younger cohort also sought out emotional support significantly more often (χ2 = 12.0, P = 
.001) via support groups and narratives of other patients’ experiences.  One limitation of 
this study is that the older cohort tended to be diagnosed 5+ years prior, while the 
younger cohort tended to have diagnoses within a year so the findings could be due to the 
timing of diagnosis rather than age.   
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 Given its prevalence, all men should be knowledgeable about prostate cancer.  
Yet there is a significant amount of men, particularly African American men, who are 
ignorant about the disease such as their personal risk factors, screening practices, and 
treatment options if they are diagnosed.  While most patients rely on medical 
professionals to provide their health knowledge, factors such as appointment time 
constraints, potential embarrassment, and anxiety can hinder this relationship.  As a 
result, patients have been increasingly using the internet to search for health information, 
due to the privacy, ease, and convivence it affords.  Even patient populations who may 
have lower internet literacy, such as the elderly or low-income minorities, have been 
shown to obtain benefits from using the internet to obtain prostate cancer information.  
However online health information can only be useful if it is accurate, unbiased, and 
understandable by patients.  Therefore, it is necessary to evaluate the current landscape of 
prostate cancer information on the internet to ensure that patients are not being given 






This study is a review of websites about prostate cancer disease, specifically regarding 
available treatments.  We utilized established formulas and instruments, routinely used to 
evaluate websites, to analyze the readability of the websites and the accuracy of the 
content.  This study will hopefully be able to shed light on the deficiencies of online 





This study utilized three search engines: Google, Bing, and DuckDuckGo.  Based 
on market shares, Google and Bing comprised approximately 90% of total searches in 
September 2019 in the US (Google – 62.4%, Bing – 25.2%).  Yahoo primarily comprises 
the last 10%, however, the Yahoo search engine has been powered by Bing since 2009, 
so they should produce almost identical results.56  Both Google and Bing can customize 
search results, though, so that two users may receive different suggested websites based 
on their past search/internet history.  DuckDuckGo, while less popular than Google and 
Bing, does not track a user’s internet history so that every person will receive the same 
results when searching the same term.  Therefore, DuckDuckGo acted as a “control” 




Inclusion Criteria for Websites 
This study examined websites that appeared on the first two search results pages 
of each search engine.  Studies have shown that most people will not go past the first 
search results page when using a search engine.  The sites listed on the first page generate 
92% of total traffic, while the second page only generates 4.8% of total traffic.57 
The following types of websites were excluded from analysis: websites that the general 
public can change like Wikipedia as the content is too dynamic to properly evaluate, 
websites that require payment or membership, websites that do not contain information 
about prostate cancer treatment, such as news articles or donation websites.  Additionally, 
websites advertised to medical professionals were excluded.  While patients may come 
across and use these websites, they were not created with the intent to teach patients 
about prostate cancer treatments or be readable for patients. All other websites, whether 
created by professional organizations, hospitals, doctors, or personal websites such as 
blogs, were included.  Google and Bing also allow companies to pay a fee in order for 
their websites to appear on a search results page, which are marked as advertisements.  
Because these sponsored websites often appear as the first website shown, they were 
included in the study as it is logical that patients could visit these websites.  In addition, 
only websites in English were in the study. 
Search Terms 
In order to determine what terms were used in the study, Google Analytics/Trends 
was used to see what terms are often searched with “prostate cancer.”  As of December 
2019, “prostate cancer symptoms” and “prostate cancer treatment” are the top searched 
 
27 
terms.  “Symptoms” was not relevant for this study, as the goal is to mimic a patient’s 
search habits post-diagnosis.  “Prostate cancer radiation” and “prostate cancer surgery” 
also appear on Google Analytics, but they were, respectively, only searched 50% and 
33% as often compared to “Prostate cancer treatment.”  Therefore, “prostate cancer” and 
“prostate cancer treatment” were the only two terms used. 
 
Data Collection 
Health literacy is defined as the ability of patients to both understand basic health 
information and services and use that information to make appropriate health decisions.58  
Therefore, this study analyzed websites on two major factors; readability and the 
reliability of the website content.  In order to assess readability, three readability formulas 
were used: Flesch-Kincaid Reading Ease (FKRE), Flesch-Kincaid Grade Level (FKGL), 
and the SMOG Index.  These formulas are based on the total number of words, sentences, 
and syllables in a text (Figure 5).  While there are many readability formulas, the SMOG 
Index has been shown to be best suited for healthcare, while the Flesch-Kincaid formulas 
are the two most commonly used.59  The readability scores of the initial website when a 
link is clicked was documented, as were any web pages one page away if they were about 
prostate cancer treatments.  A website online (https://readabilityformulas.com/) was used 





Figure 5: Formulas for Flesch-Kincaid Reading Ease, Flesch-Kincaid Grade Level, and SMOG Index 
 
In order to assess the actual website content, the DISCERN instrument was used.  
DISCERN is a questionnaire, developed by the University of Oxford Division of Public 
Health, that evaluates the quality of written information about treatment choices.  
DISCERN consists of 16 questions that assess the reliability of the source, specific details 
about treatment choice information, and an overall quality rating (Appendix A).60  While 
DISCERN was created for printed information, studies have shown that it can also be 
used to evaluate online health information.61  It is important to note that DISCERN does 
not assess the presentation or technical functionality of the website.  Data collection was 
done by one person, a current Boston University Physician Assistant student. 
Two other aspects of website data will also be collected; the source of the website 
(hospital/professional society, medical company, personal etc.) and the position of the 
website on the results search page (1st, 2nd, 3rd, etc.).  Studies have shown that a website 
in the first position generates 33% of the traffic, while the second position drops to 18% 
of traffic.  Websites in the 10th/11th position generate close to 0% of traffic.  This trend is 





The AMA and NIH recommend that all health information should not exceed a 
readability level of 6th-7th grade, which corresponds to a SMOG/FKRL score of 6-7 and a 
FKRE of 90-70.62  In order to test whether the websites significantly exceed this 
readability level (P <.05), a one sample t-test was performed between the mean 
readability scores of the websites and the recommended scores. 
There is no definitive method on how to interpret DISCERN scores.  However, 
other studies have sorted DISCERN scores into the following categories: Excellent (75-
63 points), Good (62-51 points), Fair (50-39 points), Poor (38-27 points), Very Poor (26-
15 points).63  This method also excludes question 16, as it is much more subjective in 
nature.  By using this scoring system, the mean DISCERN score can be used to evaluate 
the quality of the content.  The mean DISCERN scores for websites marked as 
advertisements and those not marked as advertisements were compared with unpaired t-
tests to determine if there is a significant difference in quality. 
 
Timeline and resources 
Because no patient information was used in this study, Institutional Review Board 
approval was not obtained.  Data collection and analysis was done from December 17th, 
2019 to January 17th, 2019.  No additional resources were needed as only a computer is 
needed since both the DISCERN instrument and readability score calculators are free 





Forty unique websites were found on the first two search result pages of Google 
and Bing; several websites, particularly those from medical organizations and those 
marked as advertisements, were repeated between multiple searches.  82% of the 
websites found through DuckDuckGo (53/65) were identical to those found through 
Google and Bing, with the 18% difference occurring on the second search results page.  
Since these websites receive minimal traffic, it was deemed that there was little bias due 
to past internet history that had to be accounted for.  Of the forty websites, sixteen were 
marked as advertisements; there was no overlap between advertisement and non-
advertisement websites.  Fourteen of the websites were excluded from analysis (Figure 
6).  Overall 26 websites were included in analysis, seven of which were marked as 
advertisements (Appendix B). 
 




The majority (53%) of non-advertisement websites were from professional 
organizations including hospitals/treatment centers, while 71% of advertisement websites 
were from commercial organizations (Figure 6).  Since placement on a search results 
page affects traffic, it should be noted that for 3 out of the 4 searches, advertisement 
websites were placed as the first and last three to five websites on the search page. 
As shown in Table 2, the mean readability scores for the websites analyzed were 
significantly greater than the AMA/NIH recommended 6th-7th grade reading level, with 
the mean grade reading level being around 10-11 [FKRE (t(25) = -10.90, p < .05), FKRL 
(t(25) = 8.81, p < .05), SMOG (t(25) = 9.05, p < .05).  In fact, only two websites were of 
a 7th grade reading level or less, neither belonging to a medical organization.  There were 
no significant differences between the mean readability of non-advertisement and 
advertisement websites for any of the readability scores used (Table 3).  
Table 2: Comparison of readability scores of websites vs. recommended values per AMA/NIH (FKRE – 70, 





























































 The mean DISCERN score for all websites was 47 (M = 46.7, SD = 11.8), which 
equates to a “Fair” rating.  There was a significant difference between the mean 
DISCERN scores for non-advertisement and advertisement websites, t(18) = 4.4, p < .05 
(Table 4).  For non-advertisement websites, the average DISCERN score was 52 (M = 
52.5, SD = 9.5), which equates to being of “Good” quality.  The majority of websites (9) 
were classified as “Good” with two receiving an excellent rating (AUA and American 
Cancer Society) and one receiving a poor rating.  On the other hand, websites marked as 
advertisements had an average DISCERN score of 36 (M = 36.2, SD = 8.3), which 
equates to a “Poor” rating.  There were no websites that scored above a “Fair” rating, and 
5 websites were considered “Poor” or “Very poor”.   
When comparing individual questions, the mean scores for non-advertisement 
websites was higher for every question except Question 7 (Does it provide additional 
sources of support/information?) and Question 10 (Does it describe the benefits of each 
treatment?).  Of note, non-advertisement websites scored very high on Question 6 (Is it 
balanced and unbiased?) and Question 14 (Is it clear that there may be more than one 
possible treatment choice?), while advertisement websites scored poorly (Table 5). 
 
Table 4: Comparison of mean DISCERN scores of non-advertisement websites and advertisement websites.  























1 2.7 2.2 
2 4.5 3 
3 3.5 2.3 
4 1.9 1.7 
5 3.1 1.7 
6 4.8 2.9 
7 2.6 2.7 
8 2.8 1.8 
9 4.8 3.4 
10 3.3 3.9 
11 4.2 3.6 
12 2.8 1.2 
13 2.9 1.7 
14 4.9 2 







This brief study reviewed the quality and readability of websites that a patient 
who has been recently diagnosed with prostate cancer may come across when searching 
the internet.  Given the increasing popularity of internet-based medical advice, it is 
important to evaluate these resources to ensure that patients are receiving the optimal 
advice and treatments. 
As predicted, online information about prostate cancer treatments have a higher 
readability level than the average patient can understand.  Therefore, when developing 
medical websites, there is a potential need to simplify the language used and avoid 
excessive jargon.  However, readability formulas may not be the most comprehensive 
method to judge a medical website’s readability, as they are only based on the complexity 
of the writing in terms of the amount of syllables/words, not the context.  It would be 
nearly impossible to thoroughly describe prostate cancer treatments without using 
medical terminology such as “prostatectomy”, which many patients may be able 
understand even with low health literacy.  Furthermore, one study showed that the 
readability scores and patient’s perception of the difficulty of medical information, 
specifically health records, do not always match.64  In order to further evaluate the 
readability of these websites, a study using focus groups of patients should be performed 
to determine if they can properly interpret online health information.  
Based on DISCERN scores, the quality of non-advertisement websites was higher 
than hypothesized with most being categorized as “good” and scoring well in both being 
unbiased and thoroughly reviewing all treatment options.  However, the quality of 
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websites marked as advertisements was much poorer overall, receiving lower overall 
scores on almost every question of the DISCERN instrument.  Most of these websites 
were biased and did not properly review alternate options for patients other than the 
advertised products.  Also problematic was that some of the websites did not advertise 
treatments for prostate cancer, with one website recommending supplements for prostate 
health, not prostate cancer.  These types of websites can be very dangerous, as patients 
could be confused to believe that these types of medicines were actual treatments.  While 
these websites are marked as advertisements, patients who are less familiar with the 
internet, including the older demographic of prostate cancer patients, may not realize this.  
Additionally, companies pay for their websites to appear in optimal positions, with many 
appearing at the top of search pages, so virtually all patients who seek out online health 
information will come across these websites. 
One limitation of this study is the potential bias introduced by only having one 
person reviewing each website.  If this study were to be repeated, multiple people should 
evaluate each website with the DISCERN tool, which would include people of varying 
education levels to improve generalizability to the prostate cancer patient population.  
This type of study would also require more time and resources to accommodate training 
on using the DISCERN tool and monetary compensation for people’s time.  Another 
limitation is only including English language websites.  This lessens the generalizability 
of the study as the quality of foreign-language prostate cancer websites could be 
inadequate as well. Lastly, the layout and functionality of the website were not evaluated.  
This study assumed that patients would be able to navigate through each website without 
 
36 
issue, but it is entirely possible that an internet naïve patient would not be able to fully 
utilize a high-quality website if the design was confusing.  
 
Summary 
While medical professionals may provide an adequate amount of information 
during patient appointments, there are still a large number of men not fully 
knowledgeable about prostate cancer, due to limited time during appointments, forgotten 
questions, and potential embarrassment.46,47 As a result, patients have to rely on outside 
resources with the internet becoming more popular due to its convenience and privacy.49  
Yet the usefulness of online health information is dependent on the quality and 
readability of the website.  Based on a review of websites found through Google and 
Bing, the readability of websites was much higher than the average patient would be able 
to understand, while the quality was on average good for websites not marked as 
advertisements, and poor for those marked as advertisements.  While these searches occur 
in a patient’s personal life, it is still imperative that medical professionals are aware of 
how a patient is obtaining medical information and the quality of these outside resources. 
 
Clinical and/or public health significance 
Due to the prevalence of prostate cancer among men, there is a large burden on 
healthcare providers to provide knowledge on screening practices and treatments.    
While many are distrusting of online health resources, this study has shown that there are 
good quality websites that can give patients a basic understanding of prostate cancer and 
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help alleviate this burden.  These resources can act as a supplement to a patient’s 
healthcare in several different ways: supplying helpful information when one does not 
have direct access to his urologist, providing access to emotional support systems, and 
allowing patients to be more active and confident in their own healthcare.  However, in 
order to properly use these resources, there has to be guidance to direct patients to 
accurate and unbiased resources.  Due to the potential for harm being done, it needs to be 
a medical professional’s responsibility to provide this teaching and ensure that any online 
resources associated with his/her practice are updated regularly.  Overall, the internet can 
be a valuable resource for prostate cancer patients and medical providers should be more 
aware of what types of information are available in order to benefit their own practices 





Section 1 – Is the Publication Reliable 
1.) Are the aims clear? 
2.) Does it achieve its aims? 
3.) Is it relevant? 
4.) Is it clear what sources of information were used to compile the publication? (other than the author 
or producer) 
5.) Is it clear when the information used or reported in the publication was produced? 
6.) Is it balanced and unbiased? 
7.) Does it provide details of additional sources of support and information? 
8.) Does it refer to areas of uncertainty? 
Section 2 – How Good is the Quality of Information on Treatment Choices? 
9.) Does it describe how each treatment works? 
10.) Does it describe the benefits of each treatment? 
11.) Does it describe the risks of each treatment? 
12.) Does it describe what would happen if no treatment is used? 
13.) Does it describe how the treatment choices affect overall quality of life? 
14.) Is it clear that there may be more than one possible treatment choice? 
15.) Does it provide support for shared decision-making? 
Section 3 – Overall Rating of the Publication (Not used in this study) 
16.) Based on the answers to all of the above questions, rate the overall quality of the publication as a 
source of information about treatment choices. 
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APPENDIX B 
List of Websites Analyzed 
 
Website Name URL 
(Non-Advertisement)  
American Cancer Society https://www.cancer.org/cancer/prostate-cancer.html 
American Urological Association  https://www.urologyhealth.org/urologic-conditions/prostate-
cancer 
Cancer Research UK  https://www.cancerresearchuk.org/about-cancer/prostate-
cancer 
Cancer Treatment Centers  https://www.cancercenter.com/cancer-types/prostate- 
 of America  cancer/about 
Centers for Disease Control  https://www.cdc.gov/cancer/prostate/basic_info/index.htm 
Healthline  https://www.healthline.com/health/prostate-cancer 
Mayo Clinic https://www.mayoclinic.org/diseases-conditions/prostate-
cancer/diagnosis-treatment/drc-20353093 
Medical News Today  https://www.medicalnewstoday.com/articles/150086.php 
Medline Plus  https://medlineplus.gov/prostatecancer.html 
National Cancer Institute  https://www.cancer.gov/types/prostate 
Prostate Cancer Foundation  https://www.pcf.org/about-prostate-cancer/ 
Prostate Cancer Free Foundation  https://prostatecancerfree.org/prostate-cancer/ 
RadiologyInfo.org  https://www.radiologyinfo.org/en/info.cfm?pg=prostate-cancer 
Seattle Cancer Care Alliance  https://www.seattlecca.org/diseases/prostate-cancer/treatment-
options 
University of Texas MD https://www.mdanderson.org/cancer-types/prostate- 
 Anderson Cancer Center  cancer.html 
WebMD https://www.webmd.com/prostate-cancer/default.htm 
ZERO https://zerocancer.org/learn/about-prostate-cancer/ 
Website Name (Advertisement) 
American Cancer Fund  https://www.americancancerfund.org/ 
Cambridge Health Alliance https://www.challiance.org/cha-services/urology-care 
Envita  https://www.envita.com/conditions/stage-4-cancer/prostate-cancer 
Erleada https://www.erleadahcp.com/ 
Jevtana  https://www.jevtanapro.com/ 
Nubeqa  https://www.nubeqahcp.com/ 
Prostate Pill Report  https://www.prostatepillreport.com/ 
Sperling Prostate Center  https://sperlingprostatecenter.com/focal-laser-ablation-new-york-
city/ 
Xgeva  https://www.xgeva.com/about-xgeva/clinical-trial-results 
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LIST OF JOURNAL ABBREVIATIONS 
Am J Med The American Journal of Medicine 
Am J Mens Health American Journal of Men’s Health 
Ann Fam Med The Annals of Family Medicine 
Arch Trauma Res Archives of Trauma Research 
Asian Pac J Cancer Prev Asian Pacific Journal of Cancer Prevention 
BioMed Res Int BioMed Research International 
BJU Int BJU International: British Journal of Urology 
BMJ BMJ: British Medical Journal 
Br J Cancer British Journal of Cancer 
Can Urol Assoc J Canadian Urological Association Journal 
Cochrane Database Syst Rev Cochrane Database of Systemic Reviews 
Cold Spring Harb Prespect Med Cold Spring Harbor Perspectives in Medicine 
Diagn Pathol Diagnostic Pathology 
Endocrinol Metab Clin North Am Endocrinology and Metabolism Clinics of North 
America 
Eur Urol European Urology 
Health Educ Res Health Education Research 
J Clin Oncol Journal of Clinical Oncology 
JMIR: J Med Internet Res Journal of Medical Internet Research 
JNCI: J Natl Cancer Inst JNCI: Journal of the National Cancer Institute 
J Urol Journal of Urology 
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NEJM: N Engl J Med New England Journal of Medicine 
Orthop Nurs Orthopaedic Nursing 
RSAP: Res Soc Adm Pharm Research in Social and Administrative Pharmacy 
Semin Cancer Biol Seminars in Cancer Biology 
Semin Oncol Nurs Seminars in Oncology Nursing 
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